US EditionUS Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025
When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments. “The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depre…
US Policy Momentum, Clinical Progress Fuel Psychedelics Market Growth in 2025
When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depres…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
